Publication:
The fuzzy world of precision medicine: deliberations of a precision medicine tumor board

Thumbnail Image

Date

2017

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Future Medicine Ltd
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

McGraw, S. A., J. Garber, P. A. Jänne, N. Lindeman, N. Oliver, L. M. Sholl, E. M. Van Allen, et al. 2017. “The fuzzy world of precision medicine: deliberations of a precision medicine tumor board.” Personalized Medicine 14 (1): 37-50. doi:10.2217/pme-2016-0074. http://dx.doi.org/10.2217/pme-2016-0074.

Research Data

Abstract

Aim: To understand how a cancer precision medicine tumor board (CPM-TB) made choices about return of results. Materials & methods: Observed CPM-TB deliberations and completed in-depth interviews with committee members. Results: Responding to complex evidence of ambiguous significance, deliberations of the CPM-TB were predicated on analytic validity and clinical utility. Members had concerns both about potential harms due to returning results based on weak evidence and about withholding potentially meaningful results. Group dynamics and the clinical experiences of individual committee members shaped their work. Conclusion: Both scientific evidence and the social context surrounding deliberations of a CPM-TB influenced decisions about return of results. Subjective elements, while present in any scientific endeavor, may carry more weight in the face of ambiguous findings.

Description

Keywords

cancer, decision-making, genomics, precision medicine, sequencing, tumor board, US

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories